000 02365nam a22004935i 4500
001 978-94-007-2418-1
003 DE-He213
005 20140220083341.0
007 cr nn 008mamaa
008 111101s2012 ne | s |||| 0|eng d
020 _a9789400724181
_9978-94-007-2418-1
024 7 _a10.1007/978-94-007-2418-1
_2doi
050 4 _aRC261-271
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a614.5999
_223
100 1 _aHayat, M.A.
_eeditor.
245 1 0 _aNeuroblastoma
_h[electronic resource] :
_bDiagnosis, Therapy, and Prognosis /
_cedited by M.A. Hayat.
264 1 _aDordrecht :
_bSpringer Netherlands,
_c2012.
300 _aXVIII, 262p. 40 illus., 24 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aPediatric Cancer,
_x2211-7997 ;
_v1
520 _aIntroduction of new technologies and their applications to neuroblastoma diagnosis, treatment, and therapy assessment are explained. Role of molecular ghenetics in diagnosis and therapy for neuroblastoma patients is detailed. Molecular detection of minimal residual neuroblastoma is described. Magnetic resonance imaging and  spectroscopy are detailed for diagnosing this solid, extracranial cancer. Targets for therapeutic intervention in neuroblastoma are identified, including targeting multidrug resistance in this cancer. Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention. The effectiveness of chemotherapy with oral irinotecan and temozolomide is explained. The role of transcription factors (GATA) in neuroblastoma pregression is  also included.
650 0 _aMedicine.
650 0 _aOncology.
650 0 _aRadiology, Medical.
650 0 _aPediatrics.
650 0 _aSurgery.
650 1 4 _aBiomedicine.
650 2 4 _aCancer Research.
650 2 4 _aPediatrics.
650 2 4 _aDiagnostic Radiology.
650 2 4 _aPediatric Surgery.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9789400724174
830 0 _aPediatric Cancer,
_x2211-7997 ;
_v1
856 4 0 _uhttp://dx.doi.org/10.1007/978-94-007-2418-1
912 _aZDB-2-SBL
999 _c104475
_d104475